HDAC9 and cancer: Because several cancer types exhibit dysfunctions in the regulation of various HDAC isoforms, a combination of the selective inhibition of HDAC isoforms relevant to the disease etiology and disease-site targeting could further enhance the utility of HDACi in cancer therapy [211].